Interim Results From A Phase I/Ii Clinical Gene Therapy Study For Newly Diagnosed Infants With X-Linked Severe Combined Immunodeficiency Using A Safety-Modified Lentiviral Vector And Targeted Reduced Exposure To Busulfan